Welcome to our dedicated page for Gossamer Bio SEC filings (Ticker: GOSS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Gossamer Bio, Inc. (GOSS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed issuer. Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on developing and commercializing seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD), and its filings offer detailed insight into this strategy.
Through current reports on Form 8‑K, Gossamer Bio reports material events such as quarterly financial results, stockholder meeting outcomes, and significant transactions. Recent 8‑K filings have described results of operations and financial condition, approval of amendments to its 2019 Incentive Award Plan, and the option agreement and plan of merger that grant Gossamer Bio the right to acquire Respira Therapeutics and its pulmonary hypertension candidate RT234. These documents outline share issuances, potential milestone payments, and other key terms.
Investors can also use this page to locate references to the company’s incentive equity plans, employment inducement awards, and stockholder voting results, which appear in filings related to annual meetings and compensation arrangements. While Forms 10‑K and 10‑Q are not reproduced here, they are accessible through EDGAR and provide comprehensive information on research and development expenses, collaboration revenue, cash resources, and risk factors tied to seralutinib and the broader pipeline.
Stock Titan enhances these filings with AI-powered summaries that explain the significance of each document in clear language. Users can quickly understand the main points of lengthy reports, track how new equity issuances affect capital structure, and see how clinical and business milestones are reflected in Gossamer Bio’s regulatory record. Real-time updates ensure that new 8‑K, 10‑Q, 10‑K, and Form 4 insider transaction filings for GOSS are surfaced as they are posted to EDGAR, helping users follow the company’s evolving disclosure history.
Gossamer Bio Inc Schedule 13G/A (Amendment No. 6) reports that The Vanguard Group holds 0 shares of Common Stock and beneficial ownership of 0% of the class as disclosed. The filing explains an internal realignment effective January 12, 2026 that caused certain Vanguard subsidiaries or divisions to report holdings separately.
Gossamer Bio, Inc. ownership disclosure: 683 Capital Partners, LP beneficially owned 5,000,000 shares of Common Stock and warrants exercisable for 4,331,304 shares. The reporting group may be deemed to beneficially own these amounts through 683 Capital Management, LLC and Ari Zweiman. The filing states this position represents approximately 3.90% of the company on an as‑adjusted basis, using 234,696,281 shares outstanding as of March 10, 2026 and including the currently exercisable warrants. The Reporting Persons report shared voting and dispositive power over the listed securities.
Gossamer Bio, Inc. reported that Chief Medical Officer Richard Aranda had a one-time repricing of certain outstanding stock options effective March 19, 2026. A series of existing options were surrendered back to the company and replaced with new options covering the same numbers of shares, but with a reduced exercise price of $0.45 per share.
According to the disclosure, all other terms and conditions of the repriced options, including vesting schedules and expiration dates under the 2019 Incentive Award Plan, remain unchanged and continue to depend on his ongoing service with the company.
Gossamer Bio, Inc. executive Caryn Peterson, EVP of Regulatory Affairs, reported a one-time repricing of multiple stock option awards effective March 19, 2026. Previously granted options were surrendered back to the company and replacement options for the same share amounts were granted with a reduced exercise price of $0.45 per share. According to the disclosure, all other terms of these options, including vesting schedules and expiration dates under the 2019 Incentive Award Plan, remain unchanged and continue to depend on her ongoing service.
Gossamer Bio Chief Commercial Officer option repricing: Gossamer Bio, Inc. adjusted stock option awards held by Chief Commercial Officer Robert Paul Smith Jr. Effective as of March 19, 2026, the company approved a one-time repricing of certain outstanding options, lowering their exercise price to $0.45 per share while keeping vesting schedules and terms unchanged. Two existing option grants for 562,500 and 572,000 shares of common stock were disposed of back to the issuer at prior exercise prices of $2.88 and $1.13 per share, and replacement options for the same respective share amounts were granted at the new $0.45 exercise price under the 2019 Incentive Award Plan.
Gossamer Bio, Inc. reported that President & CEO Faheem Hasnain had several existing stock option awards surrendered to the company and replaced as part of a one-time repricing effective on March 19, 2026. The repricing reduced the exercise price of each affected option grant to $0.45 per share while keeping all other terms, including vesting schedules and expiration dates, unchanged under the company’s 2019 Incentive Award Plan. Individual grants include, for example, 1,680,000 stock options now exercisable at $0.45 per share expiring in 2036. These are compensation-related derivative transactions rather than open-market share purchases or sales.
Gossamer Bio, Inc. reported that COO/CFO Bryan Giraudo had several existing stock option awards canceled and reissued as part of a one-time option repricing under the company’s 2019 Incentive Award Plan.
The repricing, effective March 19, 2026, reduced the exercise price of these options to $0.45 per share from prior exercise prices ranging from $0.838 to $2.88, while keeping all other terms, including vesting schedules and option terms, unchanged. These are compensation-related derivative transactions and do not involve open-market purchases or sales of common stock.
Gossamer Bio EVP Christian Waage reported a one-time stock option repricing and related option grants and cancellations. Effective as of March 19, 2026, the company approved an option repricing that reduced the exercise price of certain outstanding options to $0.45 per share under its 2019 Incentive Award Plan.
On that date, Waage received multiple new stock option awards with an exercise price of $0.45 covering an aggregate of 2,065,584 shares of common stock, while an equal number of higher-priced options with exercise prices ranging from $0.838 to $2.88 per share were surrendered to the issuer.
All other terms of the repriced options, including vesting schedules and expiration dates through 2036, remain in effect and continue to be tied to Waage’s ongoing service with Gossamer Bio.
Gossamer Bio, Inc. filed a Post-Effective Amendment (POS AM) converting its shelf registration to a non-automatic Form S-3 and provides a prospectus for the offering of up to $200.0 million of common stock, preferred stock, debt securities, warrants and units, to be sold from time to time after the effective date. The prospectus states that specific terms and amounts will be set in prospectus supplements and that offerings may be made through underwriters, dealers, agents or directly. The prospectus also discloses clinical updates: Phase 3 PROSERA topline showed a placebo-adjusted improvement in 6MWD of 13.3 meters (p = 0.0320), which missed the prespecified alpha of 0.025; the company plans to engage the FDA, including requesting a Type C meeting. Enrollment in the Phase 3 SERANATA study for PH-ILD was paused in February 2026.